New combo therapy aims to wipe out hidden leukemia cells in High-Risk patients
NCT ID NCT03128879
First seen Nov 21, 2025 · Last updated Apr 28, 2026 · Updated 14 times
Summary
This study tests whether adding venetoclax to standard ibrutinib or acalabrutinib treatment can eliminate remaining leukemia cells in patients with high-risk chronic lymphocytic leukemia (CLL). About 90 adults who have been on ibrutinib or acalabrutinib for at least a year but still have detectable disease will receive the combination. The goal is to achieve undetectable minimal residual disease in the bone marrow, indicating a deeper remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.